CTOs on the Move

BioAge Labs

www.bioagelabs.com

 
BIOAGE has a diverse team of computational biologists and medical scientists with expertise in aging and translational research. We share the vision that a synergy of machine learning approaches, high throughput human omics data, and new experimental approaches will make it possible to discover therapies that address unmet medical needs in an aging population.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioAge Labs raised $10.9M on 07/28/2017
BioAge Labs raised $23M on 01/24/2019

Similar Companies

Aspen Medical Products

Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Eye Center of Central Georgia

Eye Center of Central Georgia is a Macon, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mersana

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.

Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities.